Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Bortez 1
Beacon Pharmaceuticals PLC
Generic: Bortezomib
Safety Advices
বাংলা
English
UNSAFE
Bortez 1 may cause excessive drowsiness with alcohol.
CONSULT YOUR DOCTOR
Bortez 1 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Bortez 1 is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Bortez 1 may cause side effects which could affect your ability to drive.
Bortez 1 might cause tiredness, dizziness, fainting, or blurred vision which may affect your ability to drive.
CAUTION
Bortez 1 should be used with caution in patients with severe kidney disease. Dose adjustment of Bortez 1 may be needed. Please consult your doctor.
Limited information is available on the use of Bortez 1 in these patients.
CAUTION
Bortez 1 should be used with caution in patients with liver disease. Dose adjustment of Bortez 1 may be needed. Please consult your doctor.
Medicine Overview of Bortez 1mg/vial Injection
Introduction
Bortez 1 is used in the treatment of multiple myeloma and mantle-cell lymphoma. It shows its working by stopping or slowing down the growth of cancer cells. Bortez 1 is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may...
... Show moreUses of Bortez 1
- Multiple myeloma
- Mantle-cell lymphoma
Side effects of Bortez 1
Common
- Low blood platelets
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Psychiatric disturbances
- Nausea
- Vomiting
- Loss of appetite
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Decreased appetite
- Decreased white blood cell count (neutrophils)
- Constipation
How to use Bortez 1
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Bortez 1 works
Bortez 1 is an anti-cancer medication. It works by blocking or slowing the breakdown of proteins in cells. As a result, there is an increase in a number of proteins in the cancer cells leading to their death.
What if you forget to take Bortez 1?
If you miss a dose of Bortez 1, please consult your doctor.
Quick Tips
- Before taking bortezomib, consult your doctor if you have any of the following disease conditions: disease of liver, kidney, heart or infections like fever with rash or genital sores, diabetes, low number of red or white blood cells or bleeding problems.
- Drink plenty of fluids every day during your treatment with bortezomib.
- Tell your doctor if you are or planning to become pregnant or are breastfeeding.
- Consult your doctor if you have signs of serious brain infection such as memory loss, trouble in thinking, difficulty with walking or loss of vision.
- Do not drive or operate machinery after taking bortezomib as it may cause tiredness, dizziness, fainting or blurred vision.
Brief Description
Indication
Mantle Cell Lymphoma, Multiple Myeloma,
Administration
IV or SC Preparation Reconstitute vial with 0.9% NaCl IV administration: Add 3.5 mL to vial for final concentration of 1 mg/mL SC administration: 2.5 mg/mL: Add 1.4 mL to vial for final concentration of 2.5 mg/mL If local injection site reactions occur following SC administration, a less concentrated solution (1 mg/mL) may be administered subcutaneously IV or SC Administration Not for intrathecal (IT) use; inadvertent IT has resulted in death and is contraindicated Separate consecutive doses by at least 72 hr Give IV as a bolus over 3-5 seconds or as SC injection Give SC injection in thigh or...
... Show moreAdult Dose
Mantle Cell Lymphoma Indicated for treatment of patients with mantle cell lymphoma as first-line in previously untreated patients or those who have relapsed Previously untreated MCL 1.3 mg/m²/dose IV twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) for six 3-week cycles; may continue for 8 cycles if response is first seen at cycle 6 Give with rituximab 375 mg/m² IV, cyclophosphamide 750 mg/m² IV, and doxorubicin 50 mg/m² IV on day 1, plus prednisone 100 mg/m² IV on days 1-5 Relapsed MCL 1.3 mg/m²/dose IV/SC twice weekly for...
... Show moreContraindication
Hypersensitivity. Child. Pregnancy and lactation.
Mode of Action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26-S proteasome. It prevents targeted proteolysis that affects multiple signaling cascades responsible for normal homeostatic functions within the cell, leading to cell death.
Precaution
Hepatic or renal impairment; history of syncope, orthostatic hypotension; dehydration. Impairs ability to drive or operate machinery. Monitor for symptoms of peripheral neuropathy. Monitor closely the blood glucose levels in patients receiving oral antidiabetic agents.
Side Effect
>10%
Asthenia (61-65%)
Nausea (61-65%)
Diarrhea (51-55%)
Anorexia (41-45%)
Constipation (41-45%)
Thrombocytopenia (41-45%)
Peripheral neuropathy (IV: 16-41%; SC: 6-24%)
Pyrexia (36-40%)
Vomiting (36-40%)
Anemia (31-35%)
Arthralgia (26-30%)
Headache (26-30%)
Insomnia (26-30%)
Limb pain (26-30%)
Dizziness (21-25%)
Dyspnea (21-25%)
Edema (21-25%)
Neutropenia (21-25%)
Paresthesia (21-25%)
Rash (21-25%)
Cough (15-20%)
Dehydration (15-20%)
URI (15-20%)
Rigors, grade 4 toxicity (10-15%)
Pregnancy Category Note
Pregnancy Based on mechanism of action and findings in animals, therapy can cause fetal harm when administered to a pregnant woman; there are no studies in pregnant women to inform drug-associated risks; therapy caused embryo-fetal lethality in rabbits at doses lower than the clinical dose; advise pregnant women of potential risk to fetus Verify pregnancy status of females of reproductive potential prior to initiating treatment Advise patients of reproductive potential to use effective contraception during treatment with therapy and for at least 2 months after treatment Lactation There are no data on presence of bortezomib or metabolites in human milk,...
... Show moreInteraction
Concurrent use of amiodarone, antivirals, isoniazid, nitrofurantoin, statins may increase the chance of peripheral neuropathy. Concurrent use of antihypertensives increases the chance of hypotension.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register